当前位置:首页>产品中心>单抗/多抗>Anti-Human IL-1 alpha/IL-1F1 Reference Antibody|抗人IL-1α/IL-1F1参考抗体(靶标:人白细胞介素-1α)

Anti-Human IL-1 alpha/IL-1F1 Reference Antibody|抗人IL-1α/IL-1F1参考抗体(靶标:人白细胞介素-1α)

  • 货号:RB9THF802026
  • 价格:面议
  • 点击:313

产品介绍

产品参数

形态Liquid
宿主种属Humanized
克隆性Monoclonal
抗体亚型IgG1-kappa (DVD-Ig)
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标IL1F1, Interleukin-1 alpha, IL1A, Hematopoietin-1, IL-1 alpha, Interleukin-1 beta, IL1B, Catabolin, IL1F2, IL-1 beta
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号P01583 & P01584
背景信息Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI).
• Bacterial Endotoxin Activates the Coagulation Cascade through Gasdermin D-Dependent Phosphatidylserine Exposure., PMID:31836429
• Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis., PMID:33200890
• Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance., PMID:33037057
• The interactions between interleukin-1 family genes: IL1A, IL1B, IL1RN, and obesity parameters., PMID:35139823
• Targeting IL-1β in the Treatment of Atherosclerosis., PMID:33362770
• IL-1 family cytokines in cardiovascular disease., PMID:29198612
• Potential of cannabidiol as acne and acne scar treatment: novel insights into molecular pathways of pathophysiological factors., PMID:38904694
• IL1A and IL1B gene polymorphisms and keratoconus susceptibility: evidence from an updated meta-analysis., PMID:33978542
• Association between the IL-1A, IL-1B and IL-1R polymorphisms and lymphoma., PMID:34159887
• Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies., PMID:32825489
别名Bispecific, ABT-981, 1791411-57-8
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 572
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 667
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 564
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 442
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 557
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 578
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 518
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 515
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 390
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 447
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 693
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 604
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 691
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 568
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 377
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 602
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 712
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 732
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 685
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 528
总计 33037 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00